October 6, 2022
Aldeyra Achieves Primary Endpoint in Part 1 of Phase 3 Trial in Rare Eye Disease
Read More
October 6, 2022
UK’s MHRA Grants Crinetics Innovation Passport for Hyperinsulinism Therapy
Read More
October 5, 2022
KalVista Terminates of KVD824 Phase 2 Trial for Prophylactic Treatment of Hereditary Angioedema
Read More
October 4, 2022
Takeda to Discontinue Manufacturing Natpara for Patients with Hypoparathyroidism at End of 2024
Read More
October 3, 2022
FDA Approves Taiho’s Lytgobi Tablets to Treat Adults with IntraHepatic Cholangiocarcinoma
Read More
September 30, 2022
Amylyx Pharmaceuticals Announces FDA Approval of Relyvrio for the Treatment of ALS
Read More
September 30, 2022
FDA Expands Approval of Catalyst’s Firdapse to Include LEMS Patients 6 and Older
Read More
September 29, 2022
FDA Approves Sanofi and Regeneron’s Dupixent as First and Only Treatment for Prurigo Nodularis
Read More
September 29, 2022
FDA Grants CRISPR Therapeutics RMAT Designation for Cutaneous T Cell Lymphomas
Read More
September 28, 2022
FDA Grants Rare Pediatric Disease Designation to TriAct Treatment for Pediatric Diffuse High-Grade Gliomas
Read More
September 28, 2022
FDA Grants Priority Review to Pharming’ Leniolisib for APDS
Read More
September 27, 2022
FDA Places Partial Clinical Hold on New Participant Enrollment in Avidity’s Phase 1/2 DM1 Trial
Read More
Load More
X